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Abstract 
Background & Objective: Pizotifen is an alternative option for prophylactic treatment of migraine 
headache. This study aims to compare the efficacy and safety of pizotifen with topiramate; one of the 
most-widely used drugs in migraine prevention. Methods: This was a single blind, randomized, parallel-
group study. After a 4-week baseline evaluation, patients with episodic migraine were randomly assigned 
to get either to piramate or pizotifen for a period of 12 weeks. Patients were asked to fill a headache diary 
through the study. Headache characteristics and the possible side effects were evaluated throughout and 
at the end of trial. Results: Sixty patients aged 20 to 49 were recruited to the study. With both drugs, the 
frequency, intensity and duration of headaches were significantly reduced (p < 0.05). Except for 
headache duration, pizotifen was significantly superior to  topiramate in the headache parameters 
assessed. Total reported side effects were initially higher inpatients who received pizotifen (37 vs. 22; 
P= 0.038); however, persistent side effects were lower for pizotifen (6 vs. 10; P= 0.22).Conclusions: The 
results of this study suggest that pizotifen is a safe and effective drug in migraine prevention. 
Keywords: Migraine Prevention, Pizotifen, topiramateز 
Introduction 
 Migraine is a chronic episodic disorder characterized by recurrent headache 
mostly  with nausea, vomiting and sensitivity to light and noise. It is the most common 
headache diagnosis in neurological services in Asia and is among the top 10 most 
disabling disorders worldwide.[1,2] However, it still remains under diagnosed and 
under treated. About 15–18% of women and 6% of men suffer from migraine.[3] Many 
patients require management of individual migraine episodes, as well as prophylactic 
treatment to prevent future episodes.[4] 
  
Frequency and severity of attacks are subject to marked inter-patient and intra-
patient variability. The median attack frequency is 1.5 per month although 10 percent 
of patients have weekly attacks. Nearly 38% of migraines need prophylactic treatment; 
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nevertheless, utilization of prophylaxis continues to be low and only 3-13%of patients 
receive prophylactic treatment,5thismay be as a result of limited efficacy, a difficult 
dosage schedule or unpleasant side effects of available options; and so there is a need 
for an efficient prophylactic treatment with minimal side effects.6 Migraine 
prophylaxis involves avoidance of trigger factors, lifestyle advice followed by 
consideration of medications. Adequate prophylaxis is necessary to reduce the 
frequency and severity of migraine attacks and thereby improve the quality of life and 
prevent medication overuse headache.[7] 
Topiramate blocks voltage-sensitive sodium channels and voltage-activated 
calcium channels, inhibits glutamate release, and increases GABA levels.[8] It 
significantly reduces the mean monthly frequency of migraine in patients receiving 50-
100 mg per day.[9] The most common adverse effect with to piramate is paresthesia, 
followed by fatigue, weight loss, somnolence, psychomotor slowing, language 
problems, renal calculi, and secondary angle closure glaucoma. To piramate is similar 
in efficacy to propranolol and valproate.[10] 
Pizotifen is a serotonin antagonist.[11] There are several studies which have 
shown the usefulness of pizotifen for migraine prevention.[12,13,14] Nonetheless, 
because of side effects of drowsiness and weight gain, it is not a first choice 
prophylactic agent, and is usually used as an alternative option when other medications 
are ineffective.[15,16] The aim of this trial was to compare the efficacy and safety of 
low dose pizotifen with topiramate. The primary endpoint was a decrease in headache 
frequency at the end of a16-week study period.17 Correct diagnosis and appropriate 
prescribing are essential to reduce the individual and economic impact of this disorder. 
 
Methods 
This randomized single-blind clinical trial without placebo control was carried out 
on patients with episodic migraine who were referred to the neurology clinic of Al Sadic 
teaching hospital, Babylon, Iraq, 2018. The duration of study was 12 weeks, consisting 
of a 4-week period for baseline assessment and a subsequent 8-week period in which 
intervention was given. Patients with episodic migraine who were seeking prophylactic 
treatment were included in a primary evaluation according to International Headache 
Society (IHS)criteria.18 After a comprehensive assessment for inclusion and exclusion 
criteria, eligible patients who gave informed consent were recruited to the study. A 
research assistant who was blind to the type of intervention made all evaluations. 
The exclusion criteria were:  
1. Anyhyper sensitivity to topiramate or pizotifen; 
2. History of mental disorders;  
3.Females who were pregnant, breast feeding,or planning for pregnancy;  
4. Treatment with topiramate or pizotifen in the last three months before the study;  
5. Concurrent prophylactic treatment for migraine;  
6. Patients with headache disorders other than episodic migraine headache;  
7. Suspicious to medication overdose headache;  
8. Use of any drugs with potential preventive effects in migraine headache within three 
months before the study. 
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The inclusion criteria were:  
1. Male or female with age of entry between 19 to 50 years;  
2. Age of migraine onset should be less than 50 years old; 
3. Willing and able to be available in the following three months;  
4. Migraine headache frequency of 4 to 14 moderate-to-severe at tacks per month 
during the past three months before the study; Migraine attacks should be separated 
at least by a one-day headache-free period;  
5.History of migraine at least one year before entry; 
6. To have signed the informed consent. 
The baseline assessment was based on the headache diary completed by the 
patients during the first eight weeks of the study. The following were recorded: 
1-Demographic data; 2- Frequency of migraine headache (attacks/month);3- Intensity 
of migraine headache measured by a10- point Visual Analog Scale (mean± SD, 
VAS)19; 
4- Duration of migraine headache (mean ± SD);which is the time between starting to 
cessation of each attack. 
 
After the baseline assessment, patients were randomized to two treatment groups 
of topiramate(n = 30) or pizotifen (n = 30) for a12-week period. The prescribed dose of 
topiramate was 25 mg twice a day. Pizotifenwas started as a 0.125 mg bedtime dose. 
During the baseline assessment and intervention periods, the patients were allowed the 
use of acute medication as they had used before the study. For observations and 
outcome measurements, the patients asked to fill in a headache diary through the study. 
The efficacy of treatment was evaluated by assessing headache parameters during 
weeks 8 to 12 from randomization relative to baseline assessment. The headache diaries 
were interpreted by an expert neurologist in migraine(me).The primary endpoint was a 
reduction in the frequency of migraine attacks, and secondary end points were: (1) 
Headache intensity (mean±SD, VAS); (2) Headache duration (although it has a low 
value in parallel clinical trials of migraine prevention 20; (3) Response to treatment, 
defined as 50% or greater reduction in attacks; (4) Safety as assessed by: Side effects 
that listed in a diary and were checked at the end of weeks 2,4, 8 and 12 from 
randomization by a neurologist. For ethical approval, doctrines of current version of the 
declaration of Helsinki wereobserved.21 The Ethics Committee of Babylon University 
of medicine approved the study, and the patients were informed regarding the trialed 
sign and potential side effects. 
For statistical Analysis, results are presented as mean ± standard deviation. 
Computerized data were analyzed using SPSS 18 software. Mann-Whitney, 
independent T-test, and chi-square tests were used in the statistical analysis. P values 
of less than 0.05 considered significant.22 
 
Results 
Sixty patients enrolled into the study; 67.1% were female. The mean age of entry 
was 33.4±7.9 years (range = 20-49) and the mean age of migraine onset was 26 ± 6.3 
years old. Twenty  patients had classic and 40 had common migraines. They had 
between 4-13 attacks of migraine per month. The treatment groups were similar with 
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respect to the migraine characteristics and demographic data. The baseline 
characteristics of both treatment groups are listed in Table 1. After a 12-week period, a 
considerable improvement for all headache characteristics was observed within groups 
compared to the baseline. A statistically significant reduction was observed in headache 
frequency, intensity and response to treatment for pizotifen compared to topiramate. 
The change in headache characteristics after interventions is listed in table 2. Regarding 
safety, 30 patients reported one or more side effects during the study, 18 in the pizotifen 
group and 12 in the topiramate group. No patients discontinued prophylactic treatment 
because of adverse side effects. The side effects of topiramate and pizotifen are listed 
in table 3 and 4. The comparison between common side effects of pizotifen and 
topiramate is listed in table 5. The most frequently reported side effects of topiramate 
were increased appetite (9 patients), weight gain (6 patients) and sedation(4 patients). 
For pizotifen, the most frequently reported side effects were drowsiness (14 patients), 
dizziness (6 patients), increased appetite (6 patients) and weight gain (5 patients). 
Reported side effects by pizotifen were lessened as the study progressed and 
nevertheless, the total reported side effects were statistically higher in patients who 
received pizotifen (37 vs. 22; P=0.038, independent T test); at the end of trial, persistent 
side effects were numerically lower for the pizotifen group (6 vs. 10; P= 0.22, Mann- 
Whitney). 
 
Table 1: Baseline headache characteristics of the study subjects 
Baseline characteristics Topiramate Pizotifen P values 




Age at migraine onset(mean ± SD, 
years) 




Migraine history (mean ± SD, years) 5.2±3.5 7.4±6 0.2* 
 
Female 61.8% 52.3% 0.4** 
Type of 
migraine(number)  
classic 5 6 0.72** 
common 16  15  
Headache frequency (mean ± SD, 
attack/month) 
8 ± 3.5 9.8 ± 2.8 0.06* 
 
Headache Severity (mean ± SD, 
VAS) 
6.6 ± 2 7.7 ± 1.6 0.2# 
 
Headache Duration (mean ± SD, 
hour) 
14.2 ± 4.4 14.2 ± 4.7 0.9* 
 
Positive family history for migraine 28.5% 33.2% 0.8** 
 
Low or Uneducated 0% 10% 0.5# 
 
SD: Standard Deviation; VAS: Visual Analog Scale. 
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The weight gains of more than two kg observed in five patients who received 
pizotifen and in six patients who received topiramate. Weight gains decreased as the 
study progressed, and most patients were able to return to theirinitial weight. There was 
no significant difference between pizotifen and topiramateregarding the side effects of 
drowsiness, nausea, weight gain and increased appetite. No pathological findings were 
encountered in the laboratory tests (CBC and LFT). 
 
Table 2: Change in headache characteristics after intervention of the study 
subjects 
P value Pizotifen topiramate characteristics 
0.002* 
 




3 ± 1.3 1.7 ± 1.3 Headache severity reduction (mean ± 
SD, VAS) 




42.7% Response to treatment (> 50% fall in 
headache frequency) 
 
SD: Standard Deviation; VAS: Visual Analog Scale; NS: not significant 
*Independent t-test; #Mann-Whitney 
 
Table 3: Reported side effects in topiramate group 
Total 
reported 
End of week 
12 
End of week 
8 
End of week 
4 














42.9 9 23.8 5 
 
38.1 8 38.1 8 19 4 Increased 
appetite 




19 4 4.8 1 4.8 1 9.5 2 19 4 Sedation 
9.5 2 4.8 1 0 0 4.8 1 9.5 2 Nausea 
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66.7 14 0 
 
0 14.3 3 57.1 12 66.7 14 Drowsiness 
28.6 6 14.3 3 
 
28.6 6 28.6 6 28.6 6 Increased 
appetite 
28.6 6 0 0 4.8 1 4.8 1 23.8 5 Dizziness 
23.8 
 
5 4.8 1 14.3 3 23.8 5 19 4 
 
Weight gain 
14.3 3 0 0 4.8 1 14.3 3 14.3 3 Dry Mouth 
9.5 2 0 0 0 0 9.5 2 9.5 2 Nausea 
4.8 1 0 0 0 0 4.8 1 4.8 1 Fatigue 
4.8 
 
1 0 0 0 0 0 0 4.8 1 Mood Change 
4.8 1 0 0 0 0 
 
4.8 1 4.8 1 Anxiety 
 
Table 5: Comparison between common side effects of pizotifen and topiramate 
P value* Persistent at 
the end of 
trial 





0 0.012 14 
 
Pizotifen Drowsiness or 
sedation 





9 Pizotifen Increased 





5 Pizotifen Weight Gain 





2 Pizotifen Nausea 
1 2 topiramate 
 
*Chi-square, Fisher’s exact test, Yate’s correction; NS: not significant 
 
Discussion 
There are several studies of pizotifen for migraine prevention; some compared its 
efficacy with placebo23, and some with other drugs.24 In the present study, we 
compared the efficacy of the pizotifen with topiramate, a widely used drug for migraine 
prevention. Both drugs were useful and there was a significant improvement for all 
evaluated headache parameters, compared to baseline. In some patients even complete 
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remission of symptoms observed. On the other hand, except for headache duration, 
pizotifen was more effective than topiramate regarding the headache characteristics 
evaluated. The present study confirms the efficacy of pizotifen(in low dose) as 
evaluable choice in migraine prevention. Concerning the safety of both drugs, although 
more than two third of patients reported one or more side effects, all were mild and 
non-serious. The total reported side effects was statically higher for pizotifen, however, 
the side effects of pizotifen decreased as the study progressed and at the end of trial the 
numbers of patients with persistent side effects were lower for pizotifen. Drowsiness is 
the most worrisome side effect of pizotifen; however, it is suggested that can be reduced 
by careful dose titration.25 In this study, a third of patients in pizotifen group initially 
developed drowsiness. However, at the end of trial, no patient complained of 
drowsiness. For both drugs, the weight gain paralleled increased appetite. However, 
similar to the findings of otherinvestigators26, for pizotifen with time most of them 
returned to their initial weight. In this study we used a single nighttime dosage for 
pizotifen. Itis suggested by other investigators 27that a single nighttime dosage might 
be preferred to the three times a day dosage for reduction of weight gain.Based on 
previous studies, pizotifen has been a second line drug in migraine prevention28-
31because of major side effects (drowsiness and weight gain). However, we find that 
these side effects are not persistent if patients can to leratethem for a few weeks 
especially in low dose.32 The limitation of this trial was the absence of placebo-control; 
hence, the efficacy of drugs may be caused by the natural history of migraine or 
regression to the mean.In conclusion, the results of the present study suggest that, in 
short-term, pizotifen with the advantage of simple dosage schedule is a safe and 
effective option in migraine prevention that is superior to topiramate. 
 
Acknowledgements 
The author wish to acknowledge the contribution of Dr. Mahmoud Jasem for the 
statistical analyses.  
 
 
Conflict of Interests.  
There are non-conflicts of interest . 
 
Reference 
1- Wang SJ, Chung CS, Chankrachang S, Ravishankar K, Merican JS, Salazaret G, al. 
Migraine disability awareness campaign in Asia: migraine assessment for 
prophylaxis. Headache 2008; 48;1356-65. 
2- 2- Moriarty M, Mallick-Searle T. Diagnosis and treatment for chronic 
migraine.NursePract.2016;41(6):18–32.doi:10.1097/01.NPR.0000483078. 55590. 
b3. 
3- Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: 
epidemiology and patterns of health care use. Neurology 2002; 58:885-94. 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (28), No. (3): 2020   
0652-1992 , Print ISSN:8135-2312 ine ISSN:Onl 
                                         
 
© Journal of University of Babylon for Pure and Applied Sciences (JUBPAS) by University of Babylon is licensed under a Creative 
Commons Attribution 4. 0 International License, 2020. 
https://www.journalofbabylon.com/index.php/JUBPAS, info@journalofbabylon.com, jub@itnet.uobabylon.edu.iq 




4- Al-Quliti KW, Assaedi ES. New advances in prevention of migraine. Review of 
current practice and recent advances. Neurosciences (Riyadh). 2016;21(3):207–
214. doi:10.17712/nsj.2016.3.20150506 
5-  Silberstein SD. Preventive Migraine Treatment. Continuum (MinneapMinn). 
2015;21(4 Headache):973–989. doi:10.1212/CON.0000000000000199 
6-  Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and 
the need for preventive therapy. Neurology 2007; 68:343-9. 
7- D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient 
acceptance. Neuropsychiatr Dis Treat. 2008;4(6):1155–1167. 
8- Fenstermacher N, Levin M, Ward T. Pharmacological prevention of migraine. BMJ 
2011; 342:540-3. 
9- Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: 
efficacy, safety and patient preference. Neuropsychiatr Dis Treat. 2010;6:17–28. 
Published 2010 Feb 3. 
10- Silberstein SD, Holland S, Freitag F, et al. Evidencebased guideline update: 
Pharmacologic treatment for episodic migraine prevention in adults. Neurology 
2012; 78:1337-45. 
11- Dixon AK, Hill RC, Roemer D, Scholtysik G. Pharmacological properties of 4 (1-
methyl-4- piperidylidine)-9, 10-dihydro-4H-benzo-[4, 5] cyclohepta [1, 2]-
thiophene hydrogen maleate (pizotifen). ArzneimForsch1977; 27:1968-79. 
12- Bademosi O, Osuntokun BO. Pizotifen in the management of migraine. 
Practitioner1978;220:325-7. 
13- Heathfield KW, Stone P, Crowder D. Pizotifen in the treatment of migraine. 
Practitioner 1977; 218:428-30. 
14- Gürsoy AE, Ertaş M. Prophylactic Treatment of Migraine. Noro Psikiyatr Ars. 
2013;50(Suppl 1):S30–S35. doi:10.4274/npa.y7199 
15- Stark RJ, Valenti L, Miller GC. Management of migraine in Australian general 
practice. Med J Aust 2007; 187:142-6. 
16-Miller S. The acute and preventative treatment of episodic migraine. Ann Indian 
Acad Neurol. 2012;15(Suppl 1):S33–S39. doi:10.4103/0972-2327.99998 
17- PierangeliG ,Cevoli S, Sancisi E, et al. Which therapy for which patient? Neurol 
Sci 2006; 27:S153-8. 
18- Headache Classification Committee of the International Headache Society. Classifi 
cation and diagnostic criteria for headache disorders, cranial neuralgias and facial 
pain. Cephalalgia 1988; 8:1-96. 
19- Wewers ME, Lowe NK. A critical review of visualanalogue scales in the 
measurement of clinical phenomena. Res Nurs health 1990;13:227-36. 
20-Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs 
in migraine: A guide for investigators. Cephalalgia 2012;32:6-38. 
21- Ethical Principles for Medical Research Involving Human Subjects October 2008; 
59th WMA General Assembly. Available from: http://www.wma.net/ 
en/30publications/ 10policies/b3 
22- Daniel WW. Biostatistics A foundation for analysis in the health sciences. 9th ed. ; 
2009. Chapter seven:7.10, determining sample size to control type II errors. P. 278. 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (28), No. (3): 2020   
0652-1992 , Print ISSN:8135-2312 ine ISSN:Onl 
                                         
 
© Journal of University of Babylon for Pure and Applied Sciences (JUBPAS) by University of Babylon is licensed under a Creative 
Commons Attribution 4. 0 International License, 2020. 
https://www.journalofbabylon.com/index.php/JUBPAS, info@journalofbabylon.com, jub@itnet.uobabylon.edu.iq 




23- Osterman P. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-
5-semicarbazono-6-oxo- 2.3. 5.6.-tetrahydroindol (Divascan®) in migraine 
prophylaxis. Acta Neurol Scand1977;56:17-28. 
24- Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a 
double-blind trial. N Z Med J 1971; 73:5-9. 
25- Stark RJ, Stark CD. Migraine prophylaxis. Med J Aust 2008; 189:283-8. 
26-Dalsgaard-Nielsen T, Ulrich J. Long-time effect and tolerance during prophylactic 
treatment of migraine with a benzo-cycloheptathiophene derivative, pizotifen. 
Headache 1973; 13:12-8.  
27- Behan PO. Pizotifen in the treatment of severe recurrent headache single and 
divided dose therapy compared. Br J Clin Pract1982; 36:13-7. 
28- Silcocks P, Whitham D, Whitehouse W. P3MC: A double blind parallel group 
randomisedplacebo controlled trial of Propranolol and Pizotifen in preventing 
migraine in children. Trials 2010; 11:71. 
29-  Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-
revised report of an EFNS task force. Eur J Neurol 2009; 16:968-81. 
30- Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. Can 
Med Assoc J 2010; 182:E269-76. 
31- Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and 
prevention of migraines. AmFam Physician 2003; 67:1395-7. 
32- Ahmad C, Mohammad RN ,Foroud AZ, Rasul N,Mehri S. Pizotifen in migraine 
prevention: A comparison with sodium valproate. Neurology Asia.2012; 17(4) : 
319 – 324. 
